India, Aug. 25 -- GSK has announced the availability of its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, marking its commitment to addressing the unmet need for specialised treatments in cancer care.

Gynaecological cancers are among the most common cancers in women in India and are on the rise. Endometrial and ovarian cancers are among the top three gynecological cancers in India.By 2045, the incidence of endometrial and ovarian cancer in India is projected to increase by 78%and 69% respectively.

Jemperli is the first and only approved PD-1 immunotherapy for the second-line treatment of mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) advanced or recurrent endometrial ca...